Invicro’s early clinical imaging services deliver decision-making data for drug development teams in Phases 0, I and II. We have many years of pharma industry experience, and this understanding of the drug development process helps us design and execute pathology and imaging studies so that the resultant data reduces risk in later phases of development. We own and operate clinics in London, UK and New Haven, CT allowing us to execute studies in both Europe and North America as required. Our focus is to provide high-quality, quantitative data to:


  • Detect and measure expression of tissue biomarkers
  • Confirm drug penetration in the target tissue of interest
  • Measure of drug engagement of the desired molecular target
  • Establish evidence of modification of target activity following drug interaction
  • Evaluate early evidence of treatment response


  • PET
  • PET/CT
  • MRI
  • CT
  • Ultrasound
  • Core histology
  • Multiplex Immunohistochemistry (IHC)
  • Multiplex Immunofluorescence (IF)
  • Quanticell™ High sensitivity Immunohistochemistry (IHC)
  • RNAScope® ISH
  • BaseScope™ ISH
  • Additional Modalities Available